EDP 788

Drug Profile

EDP 788

Alternative Names: EDP-788

Latest Information Update: 24 Apr 2016

Price : *
* Final gross price and currency may vary according to local VAT and billing address.

At a glance

  • Originator Enanta Pharmaceuticals
  • Class Antibacterials; Heterocyclic bicyclo compounds; Small molecules
  • Mechanism of Action Protein synthesis inhibitors
  • Orphan Drug Status

    Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.

  • New Molecular Entity No

Highest Development Phases

  • Discontinued Methicillin-resistant Staphylococcus aureus infections

Most Recent Events

  • 24 Apr 2016 Discontinued - Preclinical for Methicillin-resistant Staphylococcus aureus infections in USA (IV)
  • 07 Jan 2015 Enanta Pharmaceuticals completes enrolment in its phase I trial in Healthy volunteers in USA (NCT02255968)
  • 01 Oct 2014 Enanta Pharmaceuticals terminates a phase I trial in Healthy volunteers in USA (PO) (NCT02255968)
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top